eligibility_summary
Include: ≥18, MM, relapsed/progressive after ≥1 prior auto SCT, ≥3 prior lines incl IMiD, PI, anti‑CD38, ≥4e6 CD34+/kg, CrCl>60, ECOG≤2. Exclude: plasma cell leukemia, CNS MM, prior allo HCT or >2 auto SCT, plasmacytoma >3 cm, cardiac/QTc issues or LVEF<40, pulmonary issues/DLCO<50%/O2, liver disease/LFTs>2×ULN, HIV+, pregnancy/breastfeeding, infection, AL amyloidosis, murine mAb allergy, RT contraindication/excess RT, recent anti‑CD38 (<30 d), prior G4 GI tox with high‑dose melphalan.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT04466475 (Phase I, withdrawn before enrollment) tested conditioning with 211At-OKT10-B10 plus melphalan before autologous PBSC transplant in relapsed/refractory multiple myeloma. 211At-OKT10-B10 is a radioimmunotherapy: a murine anti-CD38 monoclonal antibody (OKT10-B10) conjugated to the alpha-emitter astatine-211. Mechanism: binds CD38 on malignant plasma cells and delivers short-range alpha radiation to induce lethal DNA double-strand breaks. Melphalan is an alkylating chemotherapy (nitrogen mustard) that crosslinks DNA, driving apoptosis of rapidly dividing cells. Targets/pathways: CD38+ plasma cells, DNA damage/repair pathways and cell-cycle progression, marrow rescue via autologous stem cell transplantation.